Interviewed Dr. Berenson on his perspective on Abstract 1 & Abstract 2.
Questions: Reaction to results — anything surprising? Most important take home message or clinical implication.
Ruxolitinib Is Under Investigation as JAK Inhibition Strategy for Multiple Myeloma
CancerNetwork® spoke with James R. Berenson, MD, founder, medical and scientific director, and president and chief...